PDGFRB and cancer: Besides cancers with prevalent oncogenic mutations (e.g., BRAF mutation in melanoma, c-kit or PDGFR mutations in gastrointestinal stromal tumors), BTCs are now known to present one of the highest frequencies of targetable molecular alterations across cancer types [25,26,27,28,29,30].